MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.
Maille E, et al. Among authors: danel c.
Br J Cancer. 2019 Feb;120(4):387-397. doi: 10.1038/s41416-019-0379-8. Epub 2019 Feb 11.
Br J Cancer. 2019.
PMID: 30739911
Free PMC article.
Clinical Trial.